Neuro-ophthalmic challenges and multi-morbidity in vasculitis among the older adults.
暂无分享,去创建一个
[1] P. Heeringa,et al. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort , 2023, RMD Open.
[2] P. Merkel,et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis , 2022, Arthritis & rheumatology.
[3] E. Vicente-Rabaneda,et al. Utility of tocilizumab in autoimmune eye diseases , 2022, Expert opinion on biological therapy.
[4] A. Boonen,et al. Challenges in the management of older patients with inflammatory rheumatic diseases , 2022, Nature Reviews Rheumatology.
[5] E. Vicente-Rabaneda,et al. Advances in the Treatment of Giant Cell Arteritis , 2022, Journal of clinical medicine.
[6] J. Springer,et al. Diagnostic and Therapeutic Challenges of Vasculitis. , 2022, The Canadian journal of cardiology.
[7] M. Harigai,et al. Avacopan, a Selective C5a Receptor Antagonist, for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2022, Modern rheumatology.
[8] J. Burns,et al. Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.
[9] Marina F Englesakis,et al. Effects of comprehensive geriatric care models on postoperative outcomes in geriatric surgical patients: a systematic review and meta-analysis , 2021, BMC Anesthesiology.
[10] R. Mustafa,et al. Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments , 2021, ACR open rheumatology.
[11] C. Crowson,et al. Prevalence of Takayasu Arteritis: A Population-based Study , 2021, The Journal of Rheumatology.
[12] P. Cacoub,et al. Medium- and Large-Vessel Vasculitis. , 2021, Circulation.
[13] J. Pope,et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.
[14] R. Luqmani,et al. Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future , 2020, Current Rheumatology Reports.
[15] H. Patel,et al. Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice , 2020, Geriatrics.
[16] P. Merkel,et al. ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.
[17] E. Matteson,et al. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica , 2020, Nature Reviews Rheumatology.
[18] K. Temprano,et al. Cogan’s Syndrome: Clinical Presentations and Update on Treatment , 2020, Current Allergy and Asthma Reports.
[19] S. Palioura,et al. Bilateral interstitial keratitis, erythema nodosum and atrial fibrillation as presenting signs of polyarteritis nodosa , 2020, American journal of ophthalmology case reports.
[20] M. Ko,et al. Neuro-Ophthalmologic Complications of Giant Cell Arteritis: Diagnosis and Treatment , 2019, Seminars in Neurology.
[21] C. Turesson,et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.
[22] L. Arnaud,et al. Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. , 2019, Autoimmunity reviews.
[23] L. Mouthon,et al. Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. , 2019, Autoimmunity reviews.
[24] L. Guillevin,et al. Polyarteritis Nodosa Neurologic Manifestations. , 2019, Neurologic clinics.
[25] I. Chatziralli,et al. Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature , 2019, Ophthalmology and Therapy.
[26] E. Tombetti,et al. Takayasu arteritis: advanced understanding is leading to new horizons , 2019, Rheumatology.
[27] Y. Wang,et al. Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis. , 2019, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[28] Z. Amoura,et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. , 2018, Autoimmunity reviews.
[29] R. Caporali,et al. Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management , 2018, Drugs & Aging.
[30] W. Frishman,et al. Tocilizumab in Giant Cell Arteritis , 2018, Cardiology in review.
[31] R. Caporali,et al. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? , 2018, Rheumatology.
[32] G. Kuchel. Frailty and Resilience as Outcome Measures in Clinical Trials and Geriatric Care: Are We Getting Any Closer? , 2018, Journal of the American Geriatrics Society.
[33] P. Merkel,et al. Evaluation of damage in giant cell arteritis , 2018, Rheumatology.
[34] J. Rizzo,et al. Ophthalmic manifestations of giant cell arteritis. , 2018, Rheumatology.
[35] M. Isobe,et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) , 2017, Annals of the rheumatic diseases.
[36] Gillian E. Caughey,et al. What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.
[37] H. Wald,et al. Comprehensive geriatric assessment for older adults admitted to hospital. , 2017, The Cochrane database of systematic reviews.
[38] E. Matteson,et al. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota , 2017, Arthritis & rheumatology.
[39] B. Bonnotte,et al. Recent advances in our understanding of giant cell arteritis pathogenesis. , 2017, Autoimmunity reviews.
[40] K. Aksu,et al. What is new in management of Takayasu arteritis? , 2017, Presse medicale.
[41] H. Ahn,et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study. , 2017, International journal of cardiology.
[42] E. Matteson,et al. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. , 2016, Ophthalmology.
[43] C. Pui,et al. Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.
[44] E. Matteson,et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.
[45] J. Llorca,et al. Giant Cell Arteritis: Visual Loss Is Our Major Concern , 2016, The Journal of Rheumatology.
[46] B. Roche,et al. Incidence of Severe Infections and Infection‐Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double‐Cohort Study , 2016, Arthritis & rheumatology.
[47] M. Oray,et al. Long-term side effects of glucocorticoids , 2016, Expert opinion on drug safety.
[48] C. Salvarani,et al. Epidemiology of granulomatosis with polyangiitis (Wegener's granulomatosis) in Northern Italy: a 15-year population-based study. , 2014, Seminars in arthritis and rheumatism.
[49] A. Kessel,et al. Cogan syndrome--pathogenesis, clinical variants and treatment approaches. , 2014, Autoimmunity reviews.
[50] P. Merkel,et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis , 2012, Annals of the rheumatic diseases.
[51] Y. J. Liao,et al. Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.
[52] T. Therneau,et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. , 2011, Arthritis and rheumatism.
[53] C. Kallenberg. Pathophysiology of ANCA-Associated Small Vessel Vasculitis , 2010, Current rheumatology reports.
[54] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.
[55] K. Barraclough,et al. BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.
[56] D. Scott,et al. Epidemiology of ANCA-associated vasculitis. , 2010, Rheumatic diseases clinics of North America.
[57] L. Mouthon,et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. , 2010, Arthritis and rheumatism.
[58] L. Jacobsson,et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.
[59] S. Gabriel,et al. Increase in age at onset of giant cell arteritis: a population-based study , 2009, Annals of the rheumatic diseases.
[60] D. Scott,et al. The epidemiology of Takayasu arteritis in the UK. , 2009, Rheumatology.
[61] E. Matteson,et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. , 2006, Mayo Clinic proceedings.
[62] L. Mortelmans,et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.
[63] J. Llorca,et al. Giant Cell Arteritis: Disease Patterns of Clinical Presentation in a Series of 240 Patients , 2005 .
[64] C. Feighery,et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.
[65] P. Savino,et al. Poor prognosis of visual outcome after visual loss from giant cell arteritis. , 2005, Ophthalmology.
[66] S. Aymé,et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. , 2004, Arthritis and rheumatism.
[67] L. Cimino,et al. Cogan Syndrome , 2002, Cornea.
[68] N. Miller,et al. CHOROIDAL INFARCTION, ANTERIOR ISCHEMIC OPTIC NEUROPATHY, AND CENTRAL RETINAL ARTERY OCCLUSION FROM POLYARTERITIS NODOSA , 2001, Retina.
[69] L. Fried,et al. Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[70] J. Jover,et al. Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.
[71] D. Scott,et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.
[72] F. Numano,et al. Angiographic findings of Takayasu arteritis: new classification. , 1996, International journal of cardiology.
[73] J. Provenzale,et al. Neuroradiologic findings in polyarteritis nodosa. , 1996, AJNR. American journal of neuroradiology.
[74] M. Cid,et al. Clinical usefulness of temporal artery biopsy. , 1987, Annals of the rheumatic diseases.
[75] H. Yazıcı,et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. , 1984, Annals of the rheumatic diseases.
[76] B. Haynes,et al. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. , 1980, Medicine.
[77] M. Grainge,et al. Systematic review and meta analysis A systematic review and meta-analysis of the incidence rate of Takayasu arteritis , 2021 .
[78] N. Arden,et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.
[79] M. LaValley,et al. Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. , 2015, Rheumatology.
[80] M. Cesari,et al. The frailty phenotype and the frailty index: different instruments for different purposes. , 2014, Age and ageing.
[81] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[82] J. Barrier. Treatment of giant cell arteritis. , 1994, Annales de medecine interne.